单位(元)广发沪港深医药混合A(014114)利润表 |
| 报告期 |
2026/6/30 |
2025/12/31 |
2025/6/30 |
2024/12/31 |
| 收入 |
5,008,609 |
85,698,973 |
116,440,914 |
-33,764,428 |
| 利息收入 |
222,064 |
224,724 |
99,362 |
170,896 |
| 其中:存款利息收入 |
222,064 |
178,454 |
53,092 |
170,896 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
46,270 |
46,270 |
- |
| 投资收益 |
-51,418,444 |
117,770,429 |
44,436,332 |
-37,040,173 |
| 其中:股票投资收益 |
-52,624,570 |
115,915,378 |
43,238,663 |
-39,843,609 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
-827 |
364 |
- |
25,735 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
1,206,952 |
1,854,687 |
1,197,670 |
2,777,701 |
| 公允价值变动收益 |
55,306,467 |
-33,897,465 |
71,510,615 |
3,012,639 |
| 汇兑收益 |
- |
- |
- |
- |
| 其他收入 |
898,522 |
1,601,286 |
394,605 |
92,210 |
| 费用 |
6,413,347 |
7,909,123 |
2,478,259 |
4,921,358 |
| 管理人报酬 |
4,452,134 |
5,684,044 |
1,876,435 |
3,657,543 |
| 托管费 |
742,022 |
947,341 |
312,739 |
609,590 |
| 销售服务费 |
1,118,236 |
1,092,187 |
200,699 |
475,885 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
100,954 |
185,551 |
88,386 |
178,340 |
| 利润总额 |
-1,404,739 |
77,789,851 |
113,962,655 |
-38,685,786 |
| 减:所得税费用 |
- |
- |
- |
- |
| 净利润 |
-1,404,739 |
77,789,851 |
113,962,655 |
-38,685,786 |
*注:新浪财经提醒:以上数据由合作伙伴提供,仅供参考,交易请以正式公告数据为准。